Breast Cancer Clinical Trial
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer
This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the growth of tumors.
Patients with histologically-confirmed, HR-positive (ER and/or PR), HER2-negative metastatic breast cancer (MBC)
Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical ovarian suppression
Receiving first line endocrine-based therapy (tamoxifen, aromatase inhibitor, or fulvestrant; concurrent molecular therapy also allowed)
Sedentary (i.e., <60 minutes > Age >18 years
BMI ≥ 18.5
Cleared for exercise participation as per screening clearance via PAR-Q+
Cleared for study participation as per screening consultation with an MSK Exercise Physiologist
Willingness to comply with all study-related procedures
Patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled
Life expectancy <6 months
Enrollment onto any other therapeutic investigational study
Mental impairment leading to inability to cooperate
Concurrent participation in weight loss or other exercise programs
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.